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Chikungunya virus (CHIKV) and related alphaviruses
cause epidemics of acute and chronic musculos-
keletal disease. To investigate the mechanisms un-
derlying the failure of immune clearance of CHIKV,
we studied mice infected with an attenuated CHIKV
strain (181/25) and the pathogenic parental strain
(AF15561), which differ by five amino acids. Whereas
AF15561 infection of wild-type mice results in viral
persistence in joint tissues, 181/25 is cleared. In
contrast, 181/25 infection of mMT mice lacking
mature B cells results in viral persistence in joint
tissues, suggesting that virus-specific antibody is
required for clearance of infection. Mapping studies
demonstrated that a highly conserved glycine at
position 82 in the A domain of the E2 glycoprotein
impedes clearance and neutralization of multiple
CHIKV strains. Remarkably, murine and human
antibodies targeting E2 domain B failed to neutralize
pathogenic CHIKV strains efficiently. Our data sug-
gest that pathogenic CHIKV strains evade E2 do-
main-B-neutralizing antibodies to establish persis-
tence.
INTRODUCTION
Chikungunya virus (CHIKV) is a mosquito-transmitted positive-
sense enveloped RNA virus in the Alphavirus genus of the Toga-
viridae. CHIKV has caused epidemics of unprecedented scale
within the past decade in many regions of the world (Weaver
and Forrester, 2015). Beginning in 2004, CHIKV re-emerged1326 Cell Reports 16, 1326–1338, August 2, 2016 ª 2016 The Author
This is an open access article under the CC BY-NC-ND license (http://from Africa and spread to islands in the Indian Ocean and South
Pacific and countries in southern Asia. In October 2013, local
transmission of CHIKV occurred on the Caribbean island of
Saint Martin (Leparc-Goffart et al., 2014). Since that time, the vi-
rus has spread throughout much of the Americas, resulting in at
least 1.8 million confirmed and suspected cases in 45 countries
or territories (http://www.paho.org/hq/index.php?option=com_
topics&view=rdmore&cid=8379&Itemid=40931).
CHIKV infection typically presents with a sudden onset of
high fever and severe pain in peripheral joints (Borgherini
et al., 2007; Staples et al., 2009). These signs and symptoms
can resolve in a few weeks. However, in up to 50% of pa-
tients, musculoskeletal abnormalities, including joint swelling,
joint stiffness, and tenosynovitis, endure for months to years
after infection (Borgherini et al., 2008; Couturier et al., 2012;
Ge´rardin et al., 2011; Schilte et al., 2013; Sissoko et al.,
2009). Infection by related alphaviruses, such as Mayaro,
o’nyong’nyong, Ross River, and Sindbis viruses, also can
lead to chronic musculoskeletal disease in humans (Suhrbier
et al., 2012).
Mechanisms by which alphaviruses cause chronic musculo-
skeletal disease remain elusive. Limited studies of human
patients suggest that arthritogenic alphaviruses establish
persistent infections within the host (Hoarau et al., 2010;
Ozden et al., 2007; Soden et al., 2000). Persistent CHIKV
infection also has been detected in experimentally infected
mice and non-human primates. In cynomolgus macaques, in-
fectious CHIKV or CHIKV RNA is present in synovial tissue,
muscle, lymphoid organs, and the liver for weeks after infec-
tion (Labadie et al., 2010). Similarly, CHIKV RNA is present
in the spleen of aged rhesus macaques for at least 5 weeks
after initial infection (Messaoudi et al., 2013). Infection of
wild-type (WT) C57BL/6 mice with CHIKV also results in
chronic synovitis and persistence of CHIKV RNA, specifically(s).
creativecommons.org/licenses/by-nc-nd/4.0/).
Figure 1. CHIKV 181/25 Is Cleared from
Sites of Dissemination in WT Mice
(A–D) WT C57BL/6 mice were inoculated in the left
rear footpad with 1,000 PFUs of the pathogenic
CHIKV strain AF15561 or the attenuated CHIKV
strain 181/25. At the time points shown, CHIKV
RNA in the right ankle (A), left wrist (B), spleen (C),
and left ankle (D) was quantified by qRT-PCR.
(E) WT C57BL/6 mice were inoculated in the left
rear footpad with 30 PFUs of AF15561 or 68,000
PFUs of 181/25. At 28 dpi, CHIKV RNA in the right
ankle was quantified by qRT-PCR.
(F) WT C57BL/6 mice were inoculated in the left
rear footpadwith 1,000 PFUs of the virus shown. At
28 dpi, CHIKV RNA in the right ankle was quanti-
fied by qRT-PCR. Horizontal bars indicate the
mean values. The dashed lines indicate the limit of
detection.
Data are pooled from two or more independent
experiments. p values were determined by two-
way ANOVAwith a Bonferroni multiple comparison
test (A), the Mann-Whitney-test (B–E), or one-way
ANOVA with a Tukey’s multiple comparison test
(F). *p < 0.05, **p < 0.01, ***p < 0.001, ****p <
0.0001.in joint-associated tissues (Hawman et al., 2013). Consistent
with these data, long-term persistence of positive- and ne-
gative-strand CHIKV RNA persists in the feet of CHIKV-ino-
culated mice (Poo et al., 2014), and mice infected with a
recombinant CHIKV strain encoding a luciferase gene display
gene activity even 60 days post-infection (Teo et al., 2013).
Collectively, these data suggest that CHIKV persists for weeks
to months in some tissues and that the chronic musculoskel-
etal disease experienced by CHIKV patients may be due to
persistent infection or inflammation.
Here, we show that the attenuated CHIKV strain 181/25, in
contrast to its pathogenic parental strain AF15561, is cleared
from joint-associated tissues within 4 weeks of infection. We
took advantage of these disparate outcomes to investigate the
viral and host determinants of CHIKV clearance and persistence.
Our findings revealed that clearance of the attenuated 181/25
strain is impaired in Rag1/ mice, B-cell-deficient mMT mice,
and B cell receptor transgenic mice that cannot produce virus-
specific antibody and that the persistence of 181/25 in joint
tissue ofRag1/mice occurred without the acquisition of adap-
tive mutations that confer persistence in WT mice. The amino
acid at position 82 of the CHIKV E2 glycoprotein, which varies
between 181/25 and AF15561, is a major determinant of CHIKV
clearance and the potency of neutralization of multiple epidemicCell ReCHIKV strains by both murine and human
immune sera. Notably, neutralization
of AF15561 by monoclonal antibodies
(MAbs) specifically targeting E2 domain
B was inefficient relative to 181/25. Over-
all, our data suggest that virus-specific
antibody responses contribute to the
clearance of 181/25 infection and that
AF15561 evades this response by mini-mizing the effect of E2 B-domain-neutralizing antibodies to
establish persistent infection.
RESULTS
CHIKV 181/25 Is Cleared from Sites of Dissemination in
WT C57BL/6 Mice
Pathogenic CHIKV strains establish persistent infections in joint
tissues of immunocompetent WT C57BL/6 mice (Hawman et al.,
2013; Poo et al., 2014). To test whether an attenuated CHIKV
strain also establishes persistent infection in mice, we measured
viral loads in the joint tissues of WT C57BL/6 mice infected with
the attenuated CHIKV strain 181/25 and its pathogenic parental
strain AF15561 (Levitt et al., 1986), which vary by five amino
acids. WT mice were inoculated in the left rear footpad with
AF15561 or 181/25, and viral loads in the contralateral right ankle
were quantified by qRT-PCR (Figure 1A). At 3 days post inocula-
tion (dpi), 181/25-infected mice had reduced viral RNA levels in
the right ankle compared with AF15561-infected mice. These
data are consistent with previous reports demonstrating that
CHIKV strain 181/25 has diminished capacity to disseminate in
mice from the site of inoculation (Ashbrook et al., 2014; Gardner
et al., 2012). At 7 dpi, levels of viral RNA in the contralateral right
ankle of mice inoculated with 181/25 were increased comparedports 16, 1326–1338, August 2, 2016 1327
with levels at 3 dpi (p < 0.001), suggesting that 181/25 replicated
at that site. Viral loads in the right ankle at 7 and 14 dpi were com-
parable in mice infected with 181/25 or AF15561 (Figure 1A). By
21 dpi, however, levels of viral RNA in the right ankle of 181/25-
infectedmice were reduced 95-fold relative to those in AF15561-
infected mice. Similarly, at 28 dpi, high levels of viral RNA were
maintained in the contralateral right ankle of AF15561-infected
mice, whereas viral RNA was below the limit of detection in 7
of 8 mice infected with 181/25. Viral RNA in the right ankle of
AF15561-infected mice remained detectable for at least 6 weeks
post-infection (Figure 1A). Similar to the viral RNA levels in the
right ankle, viral RNA levels in thewrist (Figure 1B) and the spleen
(Figure 1C) of mice infected with 181/25 were below the limit of
detection at 28 dpi, whereas viral RNA remained detectable at
those sites in AF15561-infected animals. In contrast, viral RNA
was detectable at 28 dpi in the ipsilateral left ankle, which is
proximal to the site of inoculation (left rear footpad), of mice in-
fected with 181/25 (Figure 1D), suggesting that the kinetics or
the influence of the local microenvironment on viral RNA clear-
ance are distinct at that site.
AF15561 has a higher ratio of genome copies to plaque-form-
ing units (PFUs) than does 181/25 (Ashbrook et al., 2014). To
determine whether differences in the number of CHIKV particles
injected into mice contributed to differences in viral RNA persis-
tence or clearance, we inoculated WT mice with 6.8 3 104 BHK
cell PFUs of 181/25, an equivalent number of genomes as
contained in 1,000 BHK cell PFUs of our stock of AF15561 (as
determined by qRT-PCR; data not shown). Reciprocally, we
also inoculated WTmice with 30 PFUs of AF15561. Higher levels
of viral RNA were detectable at 28 dpi in the right ankle of
mice inoculated with 30 PFUs of AF15561 than in mice inocu-
lated with 6.8 3 104 BHK cell PFUs of 181/25, as the latter
were below the limit of detection in 8 of 11 mice (Figure 1E).
Thus, differential clearance of CHIKV strains AF15561 and
181/25 at sites of dissemination is not attributable to differences
in the amount of viral RNA between the two strains at the time of
inoculation.
Viral Determinants of CHIKV Persistence in Mice
Two mutations, I12 and R82, in the E2 glycoprotein of CHIKV
181/25 are responsible for attenuation of acute disease in
mice (Ashbrook et al., 2014; Gorchakov et al., 2012). To deter-
mine whether these mutations influenced the persistence of viral
RNA in joint tissues, we inoculated mice with 181/25 containing
E2 residue 12 reverted to a WT threonine (181/25E2 I12T), E2
residue 82 reverted to a WT glycine (181/25E2 R82G), or both
revertant mutations together (181/25E2 I12T R82G) and quantified
viral RNA levels in the right ankle at 28 dpi (Figure 1F). In com-
parison to mice infected with 181/25, mice infected with
181/25E2 I12T did not alter viral RNA levels in the right ankle at
28 dpi (Figure 1F). However, reversion of E2 residue 82 to a
glycine (181/25E2 R82G) resulted in 9 of 10mice having detectable
viral RNA in the right ankle at 28 dpi (Figure 1F), albeit at lower
levels than detected in the right ankle of mice inoculated
with AF15561. Inoculation of mice with the double revertant
181/25E2 I12T R82G restored viral RNA levels in the right ankle
at 28 dpi to those detected in AF15561-infectedmice (Figure 1F).
Although 181/25E2 I12T was cleared from the right ankle at 28 dpi,1328 Cell Reports 16, 1326–1338, August 2, 2016the level of viral RNA in the right ankle of mice infected with
181/25E2 I12T R82G was higher compared with 181/25E2 R82G-
infected mice, suggesting that a threonine at E2 residue 12 influ-
ences viral clearance when paired with the E2 R82G mutation.
CHIKV 181/25 Persists in Rag1/ Mice
Based on the kinetics of CHIKV 181/25 clearance from the
right ankle of WT mice (Figure 1A), we hypothesized that adap-
tive immune responses prevented persistence of 181/25 infec-
tion. To test this hypothesis, WT mice or Rag1/ mice, which
lack mature B and T cells, were inoculated with either AF15561
or 181/25, and viral RNA in the right ankle at 3 (Figure 2A) and
28 dpi (Figure 2B) was quantified by qRT-PCR. Similar to the
viral RNA levels in WT mice (Figure 1A), the viral RNA levels
in the contralateral right ankle of Rag1/ mice at 3 dpi were
reduced in 181/25-infected mice in comparison to AF15561-in-
fected mice (126-fold; p < 0.05) (Figure 2A), suggesting
that the lower viral loads of 181/25 in this tissue at this time
point are not due to the functions of B or T lymphocytes.
AF15561-infected Rag1/ mice had higher viral RNA levels
in the right ankle at 28 dpi in comparison to AF15561-infected
WT mice (26-fold; p < 0.05) (Figure 2B), indicating that B or
T cell responses (or both) contribute to the control of
AF15561 infection but fail to mediate clearance. In compari-
son, viral RNA levels in the right ankle of 181/25-infected
Rag1/ mice at 28 dpi were 8,000-fold higher than those
in 181/25-infected WT mice (p < 0.0001) (Figure 2B). In addi-
tion, viral RNA levels in the right ankle of 181/25- and
AF15561-infected Rag1/ mice at 28 dpi were similar (Fig-
ure 2B). To confirm these findings, we measured the amounts
of infectious virus present in the serum and right ankle at 28
dpi. 181/25- and AF15561-infected Rag1/ mice had detect-
able viremia (Figure 2C), although 181/25-infected Rag1/
mice had reduced levels relative to AF15561-infected mice
(9.5-fold; p < 0.01). However, 181/25-infected Rag1/ mice
had increased titers of infectious virus in the right ankle at 28
dpi compared with the same tissue of AF15561-infected
mice (4.4-fold; p < 0.05) (Figure 2D). These data suggest that
CHIKV strains 181/25 and AF15561 exhibit a similar capacity
to persist in joint-associated tissues in the absence of adaptive
immune responses.
Reversion of attenuating mutations occurs in certain tissues
of 181/25-infected WT mice (Ashbrook et al., 2014; Gorchakov
et al., 2012). Therefore, we next determined whether persis-
tence of 181/25 in Rag1/ mice was associated with reversion
of attenuating mutations or the acquisition of other adaptive
mutations. Consensus sequencing of the E2 gene in viral
RNA isolated from the right ankle of 181/25-infected Rag1/
mice did not reveal reversion of the mutations at E2 residues
12 or 82 (data not shown). This sequencing strategy does not
exclude the presence of compensatory mutations outside the
region sequenced or low-frequency variants that could act in
a trans-complementing manner to enhance virulence (Vignuzzi
et al., 2006). To test whether persisting virus in ankle tissue
of 181/25-infected Rag1/ mice acquired the capacity to
persist in WT mice, we inoculated WT C57BL/6 mice with 6
PFUs of CHIKV from the right ankle tissue homogenates (based
on the virus titer, 6 PFUs was the amount present in 20 ml of
Figure 2. CHIKV 181/25 Persists in Rag1/
Mice
(A–D) WT or Rag1/ mice were inoculated with
1,000 PFUs of AF15561 or 181/25. At 3 dpi of
Rag1/ mice (A) or 28 dpi of WT or Rag1/ mice
(B), viral RNA in the right ankle was quantified by
qRT-PCR. Infectious virus in the serum (C) or right
ankle (D) was quantified by plaque assay.
(E) WTmice were inoculated in the left rear footpad
with clarified ankle tissue homogenate containing
6 PFUs of virus from AF15561- or 181/25-infected
animals (D) or 6 PFUs of CHIKV strain AF15561. At
28 dpi, CHIKV RNA in the right ankle was quanti-
fied by qRT-PCR. Horizontal bars indicate mean
values. Dashed lines indicate the limit of detection.
Data are from two or more independent experi-
ments. p values were determined by Student’s
t test (A and D) or one-way ANOVA with a Tukey’s
multiple comparison test (B, C, and E). *p < 0.05,
**p < 0.01, ****p < 0.0001.homogenate) from AF15561- or 181/25-infected Rag1/ mice
at 28 dpi. As a control, mice were inoculated with a similar dose
of AF15561 stock virus. At 28 dpi, high levels of viral RNA were
detected in the right ankle of mice infected with Rag1/ ankle-
derived AF15561 or 6 PFUs of stock AF15561 (Figure 2E). In
contrast, viral RNA levels in the right ankle of all WT mice
inoculated with Rag1/ ankle-derived 181/25 remained below
the limit of detection. Additionally, WT mice inoculated with
Rag1/ ankle-derived AF15561 and 181/25 had high levels
of CHIKV-specific immunoglobulin G (IgG) in the serum
(1:8,000 to 1:64,000) at the time of harvest (data not shown),
indicating that all mice had become infected. These results
suggest that in the absence of B and T cell immunity, CHIKV
strain 181/25 establishes a persistent infection without
acquiring adaptive mutations that alter the capacity for viral
persistence in WT mice.
B Cells and Virus-Specific Antibody Are Required for
Clearance of CHIKV 181/25
To determine whether B cells are required for clearance of
CHIKV 181/25 from joint tissues, we inoculated WT mice or
mMT mice (deficient in mature B cells) with either AF15561 orCell Re181/25 and quantified viral loads in the
right ankle at 28 dpi (Figure 3A). Although
not statistically significant (p > 0.05),
we found that similar to the viral loads
in Rag1/ mice, viral loads in AF15561-
infected mMT mice trended higher
compared with WT animals. Moreover,
mMT mice were unable to control 181/25
infection, with 10 of 10 mice having
persistent viral RNA in the right ankle in
comparison with 181/25-infected WT
mice (155-fold; p < 0.0001). Furthermore,
the levels of viral RNA in the right ankle
of mMT mice infected with AF15561 or
181/25 were similar. These findings sug-gest that B cells are required for clearance of 181/25 infection
in joint tissues.
As mMTmicemay have altered T cell responses because of the
antibody-independent functions ofmatureBcells (Homann et al.,
1998), we repeated these experiments using MD4 transgenic
mice (MD4tr), which express a B cell receptor (BCR) specific for
hen egg lysozyme (HEL) on a WT C57BL/6 background. In these
mice, greater than 90% of B cells express the HEL-specific BCR
due to allelic exclusion (Goodnowet al., 1988). Similar to infection
of mMTmice, infection of MD4tr mice with CHIKV strain AF15561
resulted in modestly elevated (6-fold) levels of viral RNA in the
right ankle at 28 dpi comparedwithWTmice, although this differ-
ence was not statistically significant. In contrast, levels of viral
RNA in the right ankle at 28 dpi in 181/25-infected MD4tr mice
were higher in comparison to 181/25-infected WT mice (350-
fold; p < 0.0001) (Figure 3A) and closely matched the levels
observed in mMT mice. Moreover, levels of viral RNA in the right
ankle of 181/25- and AF15561-infected MD4tr mice at 28 dpi
were similar (p > 0.05) (Figure 3A). Analysis of the CHIKV-specific
antibody response in these mice by ELISA confirmed markedly
diminished or absent CHIKV-specific IgG in AF15561- and
181/25-infected MD4tr and mMT mice (Figure 3B). These resultsports 16, 1326–1338, August 2, 2016 1329
Figure 3. Virus-Specific Antibody Is Required to Control 181/25
Infection
(A and B) WT, B-cell-deficient mMT, or BCR transgenic MD4tr C57BL/6 mice
were inoculated in the left rear footpadwith 1,000PFUsofAF15561or 181/25.At
28dpi, CHIKVRNA in the right anklewas quantifiedbyqRT-PCR (A) andCHIKV-
specific IgG in the serum was quantified by a whole-virion-based ELISA (B).
Data are from twoormore independent experiments. p valueswere determined
by one-way ANOVA with a Tukey’s multiple comparison test. ****p < 0.0001.suggest that CHIKV-specific antibody responses are required for
clearance of 181/25 from joint tissue, but the persistent AF15661
strain evades these clearance mechanisms.
Antibody Responses to CHIKV AF15561 and 181/25
Infection Are Distinct
The magnitude of the CHIKV-specific IgG response was similar
at day 28 dpi in AF15561- and 181/25-infected WT mice (Fig-
ure 3B). Next, we investigated whether differences in clearance1330 Cell Reports 16, 1326–1338, August 2, 2016of CHIKV AF15561 and 181/25 infection from joint tissue of WT
mice were associated with differences in the kinetics or quality
of the anti-CHIKV antibody response. Using a virion-based
ELISA to quantify CHIKV-specific IgM and IgG present in the
sera of WT mice, we found that virus-specific IgM responses
to both AF15561 and 181/25 infection developed rapidly, with
IgM titers peaking at 5 to 7 dpi and declining thereafter (Fig-
ure 4A). Levels of anti-CHIKV IgM were higher in AF15561-in-
fected mice at both 5 (10-fold; p < 0.0001) and 7 dpi (2.5-fold;
p < 0.0001) compared with those in 181/25-infected mice (Fig-
ure 4A). CHIKV-specific IgG responses also developed rapidly,
with titers detected at 7 dpi with either strain (Figure 4B). Again,
the levels of anti-CHIKV IgG in AF15561-infected WT mice at
7 dpi were higher than those detected in 181/25-infected mice
(12-fold; p < 0.0001). By 14 dpi and after, CHIKV-specific IgG
titers were equivalent in AF15561 and 181/25-infected mice
(Figure 4B) as were the individual CHIKV-specific IgG subtypes
at 28 dpi (Figure 4C). By these analyses, the principal differences
in virus-specific antibody responses during AF15561 or 181/25
infection occurred at early times post-infection; higher antibody
levels were detected in AF15561-infected animals, which likely
reflects the greater levels of viral replication and antigen in these
mice.
Although early virus-specific IgM and IgG responses were
greater after infection with AF15561 compared with 181/25,
this pattern did not correlate with clearance of AF15561 and
181/25 from joint tissue of WT mice. Given this lack of correla-
tion, we investigated the qualitative activity of the virus-specific
antibody response by measuring the neutralization capacity us-
ing a plaque reduction neutralization test (PRNT50) with 181/25 or
AF15561 as the challenge viruses. When serum was collected at
7 dpi from AF15561- or 181/25-infected mice and tested against
the homologous virus, serum from 181/25-infected mice dis-
played greater neutralizing activity compared with serum from
AF15561-infected mice (22-fold; p < 0.0001) (Figure 5A). How-
ever, serum from AF15561-infected mice displayed neutralizing
activity against 181/25 that was comparable to serum from
181/25-infected mice (Figure 5A), despite the differences in
IgM and IgG ELISA binding titers at this time point (Figures 4A
and 4B). By combining the ELISA and neutralization data, we
observed a lower (5.2-fold; p < 0.01) serum neutralization index
(Suthar et al., 2010) in AF15561-infected mice compared with
181/25-infected mice (Figure 5B), suggesting that the early vi-
rus-specific antibody response qualitatively differed during
infection with acutely cleared (181/25) or persistent (AF15561)
CHIKV strains. Serum collected from 181/25-infected mice at 7
dpi exhibited reduced neutralizing activity (Figure 5A) and a
reduced neutralization index (Figure 5B) against AF15561
compared with 181/25. Although we detected similar neutraliza-
tion activity against 181/25 or AF15561 virus in serum collected
at 28 dpi from AF15561- or 181/25-infected mice, the neutral-
izing activity of sera from mice infected with either virus was
consistently reduced against AF15561 compared with 181/25
(Figures 5C and 5D). Accordingly, and similar to 7 dpi, we
observed a lower serum neutralization index for sera from
AF15561- or 181/25-infected mice against AF15561 (Figure 5D).
To determine whether amino acid differences between 181/25
and AF15561 explained the differences in serum neutralization
Figure 4. Virus-Specific Antibody Responses in WT Mice Infected
with AF15561 or 181/25
(A and B) WT C57BL/6 mice were inoculated in the left rear footpad with 1,000
PFUs of AF15561 or 181/25 (n = 5–8mice per group). At the time points shown,
a virion-based ELISAwas used to quantify the serum endpoint titers of CHIKV-
specific IgM (A) or IgG (B).
(C) IgG sub-type-specific detection antibodies were used to quantify IgG
subtypes present in serum at 28 dpi (n = 5–6 mice per group).
Data are from two or more independent experiments. p values were deter-
mined by two-way ANOVA with a Bonferroni multiple comparison test (A and
B) and Student’s t test (C). *p < 0.05, **p < 0.01; ***p < 0.001, ****p < 0.0001.capacity, we performed PRNT50 assays using sera from 181/25-
infected mice against AF15561, AF15561E2 G82R, 181/25, and
181/25E2 R82G viruses. In comparison to neutralization of 181/
25, the neutralizing activity of sera collected from 181/25-in-
fected mice was reduced against AF15561 and 181/25E2 R82G,
but not AF15561E2 G82R (Figure 5E). Similar results were
observed using sera collected from AF15561-infected mice (Fig-
ure 5F). Introduction of the E2 G82Rmutation into the genome of
another epidemic CHIKV strain (SL15649) (Morrison et al., 2011)
also enhanced neutralization of the virus by serum collected from
SL15649-infected mice (Figure 5G). Furthermore, the neutral-
izing activity of human sera collected from individuals who ac-
quired CHIKV infection in the Caribbean (Figures 6A–6C) (Miner
et al., 2015) or Sri Lanka (Figures 6E–6H) was reduced against
AF15561 (an Asian genotype virus with genetic similarity to
CHIKV strains circulating in the Caribbean) and SL15649 (an
East, Central, South Africa genotype virus isolated during 2006
outbreak in Sri Lanka) in comparison with AF15561E2 G82R and
SL15649E2 G82R. Control human sera had no effect on CHIKV
infection (Figures 6D and 6I). Thus, the amino acid at E2 residue
82 influences the neutralization of epidemic Asian and East,
Central, South Africa (ECSA) genotype CHIKV strains by both
murine and human immune sera.
To define the structural basis for differences in neutralization,
we tested a panel of recently characterized CHIKV-specific
mouse and human monoclonal antibodies (MAbs) with mapped
epitopes in E1 and E2 (Fox et al., 2015; Long et al., 2015; Smith
et al., 2015; Sun et al., 2013) for the capacity to neutralize
AF15561 and 181/25. MAbs recognizing the CHIKV E1 glycopro-
tein (CHK-166, CHK-269, and CHK-155) or E2 domain A or Arch
region (h4J21 and h4N12) (see Figure S1 for domain organization
of E2) had similar neutralizing activity against AF15561 and 181/
25 (Figures 7A–7E). The neutralizing activity of MAbs that bind
epitopes spanning E2 domains A and B (CHK-152 [Pal et al.,
2013; Sun et al., 2013] and 5M16 [Long et al., 2015]) was reduced
modestly against AF15561 compared with 181/25 (2-fold and
3-fold, respectively) (Figures 7F and 7G). In contrast, mouse
and human MAbs recognizing epitopes within the E2 B domain
(CHK-265, CHK-98, CHK-48, and h8I4) neutralized AF15561
much less efficiently than 181/25 (17-fold, 11.5-fold, 19-fold,
and 600-fold respectively) (Figures 7H–7K) even though poly-
morphic E2 residues 12 and 82 are located within the E2 A
domain and not within the binding footprint of CHK-265, CHK-
98, CHK-48, or h8I4 (Fox et al., 2015; Smith et al., 2015). As
expected, West Nile virus-specific mouse and human polyclonal
antibodies had no effect on virus infection (Figures 7L and 7M).
These findings, alongwith the serum neutralization data, suggestCell Reports 16, 1326–1338, August 2, 2016 1331
Figure 5. Serum Neutralization of CHIKV
Strains
(A–D) WT C57BL/6 mice were inoculated in the left
rear footpadwith1,000PFUsofAF15561or 181/25.
At 7 (A) or 28 dpi (C), the neutralization capacity of
serum was quantified using a plaque reduction
neutralization test 50 (PRNT50) with AF15561 or
181/25 as the challenge virus. A neutralization
index was calculated using the formula (PRNT50)/
(IgG + IgM ELISA endpoint) (B and D).
(E–G) The neutralizing activity of pooled serum
derived from 181/25- (E), AF15561- (F), or
SL15649-infected mice (G) at 28 dpi was deter-
mined using the indicated viruses. Horizontal bars
indicate mean values.
Data are from two or more independent experi-
ments. Dashed lines indicate the limit of detection.
p values were determined by one-way ANOVA
with a Tukey’s multiple comparison test. *p < 0.05,
**p < 0.01 ***p < 0.001, ****p < 0.0001.
See also Figure S2.that E2 residue 82 influences neutralization of CHIKV, with path-
ogenic strains evading the inhibitory activity of antibodies target-
ing the B domain of the E2 glycoprotein.
DISCUSSION
Long-term clinical sequelae are a common outcome of infection
with CHIKV and several related alphaviruses (Suhrbier et al.,
2012). In this study, we found that in contrast to pathogenic
CHIKV strain AF15561, attenuated CHIKV strain 181/25
was cleared from most tissues of infected WT mice within
4 weeks of infection. We reasoned that comparative studies of1332 Cell Reports 16, 1326–1338, August 2, 2016CHIKV AF15561 and 181/25 infection
would reveal mechanisms that influence
clearance and persistence of CHIKV
infection.
Viral Determinants Influence CHIKV
Clearance and Persistence
Genomes of CHIKV strains AF15561 and
181/25 differ at five non-synonymous
and five synonymous nucleotide posi-
tions (Gorchakov et al., 2012). Mutations
resulting in amino acid changes in 181/
25 are in nsP1 (T301I), E2 (T12I and
G82R), 6K (C42P), and E1 (A404V). We
found that reversion of an arginine to a
glycine at E2 position 82 (181/25E2 R82G)
yielded increased viral loads in the contra-
lateral ankle at 28 dpi, suggesting that an
arginine at E2 residue 82 restricts CHIKV
persistence. Arginine 82 in E2 enhances
the affinity of CHIKV particles for glycos-
aminoglycans (GAGs) in vitro (Silva et al.,
2014), which may limit the capacity of
CHIKV to disseminate from early sites of
primary replication in vivo (Ashbrooket al., 2014; Gardner et al., 2012; Gardner et al., 2014). The extent
to which altered interactions with GAGs influences CHIKV clear-
ance remains to be determined, but our data suggest that an
arginine at position 82 promotes CHIKV clearance by facilitating
neutralization of infectious viral particles by antibodies. An argi-
nine at position 82 also was found to impair cell-to-cell spread of
CHIKV in vitro, a mechanism by which CHIKV may evade anti-
body mediated neutralization; however, this mechanism has
not been explored in vivo (Lee et al., 2011). We also found that
the amino acid at E2 position 12 contributes to persistence of
CHIKV in joint tissue, as mice infected with 181/25 encoding
both revertant mutations together (181/25E2 I12T R82G) had
Figure 6. E2 Residue 82 Influences Neutralization of CHIKV with Human Immune Sera
(A–C and E–H) The neutralizing activity of human sera from CHIKV-immune subjects—10395 (A), 10403 (B), 10406 (C), CH-002 (E), CH-009 (F), CH-014 (G), and
CH-027 (H)—was quantified using PRNT50 analysis against the indicated viruses.
(D and I) Non-immune human sera were included as a control against AF15561 (D) and SL15649 (I) WT and mutant viruses. The serum dilutions at which 50% of
AF15561 (red text), AF15561E2 G82R (black text), SL15649 (pink text), or SL15649E2 G82R (blue text) was neutralized (PRNT50) were determined by non-linear
regression (95% CI). Each graph represents the mean and SEM from two independent experiments.
See also Figure S2.
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Figure 7. Differential Neutralization of AF15561 and 181/25 by MAbs Targeting E2 Domain B
(A–M) MAbs CHK-166 (A), CHK-269 (B), CHK-155 (C), h4J21 (D), h4N12 (E), CHK-152 (F), h5M16 (G), CHK-265 (H), CHK-98 (I), CHK-48 (J), and h814 (K) were
incubated with 100 FFUs of AF15561 (red) or 181/25 (blue) viruses at 37C for 1 hr. MAb-virus mixtures were added to Vero cells and incubated for 18 hr. Virus-
infected foci were stained and counted.Wells containingMAbswere comparedwith wells withoutMAbs to determine relative infection. WNVE60 (L) and hE16 (M)
MAbs were included as isotype control MAbs. The concentrations at which 50% of AF15561 (red text) or 181/25 (blue text) were neutralized (EC50) was
determined by non-linear regression and are displayed in nanograms per milliliter (95% CI). Each graph represents the mean and SD from at least two inde-
pendent experiments.
See also Figures S1 and S2.
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increased levels of persistent viral RNA in joint tissue at late
times post-infection compared with mice infected with either
181/25E2 R82G or 181/25E2 I12T. Although the mechanism by
which a threonine at E2 position 12 enhances viral burden during
the persistent phase of infection requires further study, E2 posi-
tion 12 may stabilize the residue at E2 position 82 (Gorchakov
et al., 2012). In addition, for Semliki Forest virus, a related alpha-
virus, a threonine at E2 position 12 increases the pH threshold of
viral fusion (Glomb-Reinmund and Kielian, 1998), which might
enhance replication efficiency.
CHIKV 181/25 Persists in Mice Lacking the Capacity to
Produce Virus-Specific Antibodies
Pathogenic strains of CHIKV persist in joint tissue of mice, sug-
gesting that adaptive immune responses fail to clear primary
infection (Hawman et al., 2013; Poo et al., 2014). In contrast,
adaptive immune responses efficiently clear attenuated strain
181/25. Rag1/ mice infected with 181/25 exhibited a nearly
8,000-fold increase in viral load in joint tissue distal to the site
of inoculation at 28 dpi relative to 181/25-infected WT mice.
In addition, levels of viral RNA and infectious virus in the contra-
lateral joint tissue of 181/25-infected Rag1/ mice were similar
or greater than those detected in AF15561-infected Rag1/
mice. Increased titers of infectious virus in joint tissues of
181/25-infected Rag1/ mice may be due to the enhancement
of viral replication within tissues by efficient interactions with
GAGs, as has been described for a GAG-binding strain of
Sindbis virus (Ryman et al., 2007). Infectious virus recovered
from joint tissue of 181/25-infected Rag1/ mice at 28 dpi
had not gained the capacity to establish persistence in WT
mice, and reversion of the mutations in the E2 glycoprotein
was not detected. Therefore, in mice lacking adaptive immune
responses, AF15561 and 181/25 establish persistence in joint
tissues with comparable efficiency.
Our findings that Rag1/ mice infected with 181/25 had
detectable viremia at 28 dpi contrast with a previous study in
which older 8-10 week old Rag1/ C57BL/6 mice infected
with 181/25 did not have detectable viremia (Seymour et al.,
2015). Additionally, we consistently detected infectious virus
at 28 dpi in joint tissues of Rag1/ mice infected with 181/
25. In contrast, Seymour et al. did not detect infectious virus
at late times post-infection (28-56 dpi) in various tissues of
181/25-infected Rag1/ mice, although joint tissues were
not examined. It is possible that the age of mice and specific
tissues evaluated in the two studies accounts for the disparate
findings. Absence of detectable genetic or phenotypic rever-
sion of 181/25 virus after 4 weeks of viral persistence in the
joint tissue of Rag1/ mice also differs from studies of 181/
25-infected WT mice in which rapid reversion of the attenu-
ating mutations in virus present in the circulation and the
spleen was detected (Ashbrook et al., 2014; Gorchakov
et al., 2012). Deep sequencing of CHIKV from the serum, brain,
or kidney of persistently infected Rag1/ mice revealed small
numbers of mutations, suggesting that CHIKV is under less se-
lective pressure in Rag1/ mice than WT mice (Poo et al.,
2014; Seymour et al., 2015). Collectively, these data suggest
that reversion of the attenuating mutations in 181/25 in WT
mice likely is driven, at least in part, by adaptive immune re-sponses. Similar to our findings with Rag1/ mice, 181/25
infection of B cell deficient mMT mice or BCR transgenic
mice that have normal B cell numbers but are incapable of
producing CHIKV-specific antibody, resulted in persistence
of viral RNA in joint tissue at levels similar to those in
AF15561-infected WT mice. These findings suggest that
CHIKV-specific antibody responses are essential for clearance
of 181/25 from joint tissue, and that the pathogenic AF15561
strain evades these clearance mechanisms.
Antibody Responses to Pathogenic and Attenuated
CHIKV Strains Are Distinct
Characterization of the humoral immune response of WT mice
to AF15561 and 181/25 infection revealed differences in the ki-
netics, magnitude, and quality of the antiviral antibody
response. Similar to previous studies (Her et al., 2014; Lum
et al., 2013), the anti-CHIKV IgM response peaked at day 5 af-
ter AF15561 infection. In comparison, the anti-CHIKV IgM
response in 181/25-infected mice was of lower magnitude
and peaked slightly later (7 dpi). AF15561 infection of WT
mice also induced a rapid CHIKV-specific IgG response, with
high antibody levels detected at 7 dpi. In contrast, 181/25-in-
fected mice did not achieve similar CHIKV-specific IgG titers
until 14 dpi. Thus, the kinetics and magnitude of the early
virus-specific IgM and IgG response did not correlate with
relative clearance of AF15561 and 181/25 in joint tissue of
WT mice. In addition, characterization of the neutralizing anti-
body response in AF15561 and 181/25-infected mice revealed
three important findings: (1) the neutralization capacity of sera
from AF15561-infected and 181/25-infected mice differed
when homologous virus was used in the in vitro neutralization
assay, with lower neutralizing titers detected in sera from
AF15561-infected mice at both 7 and 28 dpi. Given the higher
ELISA titers detected in these mice, this difference resulted in
a diminished neutralization index. (2) When day 7 sera from
AF15561-infected mice were tested against the heterologous
181/25 virus, we detected a lower neutralization index in com-
parison to day 7 sera from 181/25-infected mice. These find-
ings indicate that the higher levels of CHIKV-specific IgM
and IgG antibodies in sera from AF15561-infected mice do
not translate to a higher CHIKV-neutralizing capacity, particu-
larly at early times post-infection. Differences in the quality of
CHIKV-specific antibody responses could contribute to the
difference in clearance of the two viruses in WT mice. Early
neutralizing antibody responses in humans protect against
acute disease (Yoon et al., 2015), and the appearance of
neutralizing IgG3 antibodies in CHIKV-infected patients corre-
lates with reduced chronic CHIKV-induced musculoskeletal
disease (Kam et al., 2012). (3) The neutralization capacity of
sera from 181/25-infected mice against AF15561 was lower
in comparison to the neutralization capacity of the same sera
against the homologous virus. Although sera from AF15561-in-
fected mice did not neutralize 181/25 as efficiently as sera
from 181/25-infected mice, sera from AF15561-infected
mice neutralized 181/25 to a greater extent than it did
AF15561. These findings suggest that differences in the
display of neutralizing epitopes in AF15561 and 181/25 virions
contribute to differential inhibition by serum. Consistent withCell Reports 16, 1326–1338, August 2, 2016 1335
this hypothesis, the neutralization capacity of sera collected
from CHIKV-infected mice or humans in Sri Lanka and the
Caribbean was enhanced against mutated epidemic CHIKV
strains encoding an arginine at E2 position 82.
181/25 Is More Efficiently Neutralized by Anti-CHIKV
Antibodies Targeting E2 Domain B
To determine the molecular basis underlying differences in
antibody-mediated neutralization of 181/25 and AF15561, we
performed neutralization assays using a panel of MAbs targeting
epitopes in distinct domains of the CHIKV E1 and E2 glycopro-
teins. MAbs recognizing epitopes in the E1 glycoprotein, E2
domain A, or E2 Arch region had equivalent neutralizing activity
against AF15561 and 181/25. Importantly, this finding suggests
that differences in PFU-to-antigen ratios of the viruses do not
explain the differential neutralization of the two viruses by sera
from virus-infected mice. In contrast, several mouse and human
MAbs targeting E2 domain B exhibited reduced neutralization
capacity against AF15561 compared with 181/25. These find-
ings are consistent with reports that examined the mechanism
of neutralization by the E2 B domain specific anti-CHIKV MAb
5F10 (Lee et al., 2011; Porta et al., 2015). Passage of a CHIKV
isolate containing an arginine at E2 position 82 under selective
pressure of MAb 5F10 selected for a glycine at position 82
(Lee et al., 2011), and structural studies suggested that 5F10
neutralizes CHIKV encoding an arginine at E2 position 82 by
locking domain B into a rigid conformation and preventing expo-
sure of the E1 fusion loop (Porta et al., 2015). Although 5F10
binds to CHIKV strains possessing a glycine at E2 position 82,
the binding does not inhibit fusion. This mechanism of locking
domain B and preventing fusion appears to be common to
both mouse and human neutralizing antibodies targeting E2
domain B (Fox et al., 2015; Long et al., 2015; Sun et al., 2013).
In our studies, MAb CHK-265, which neutralizes CHIKV by
cross-linking E2 domain B to E2 domain A of an adjacent spike
(Figure S2) (Fox et al., 2015), exhibited a substantial difference
in EC50 values between AF15561 and 181/25. The mutations in
181/25 at positions 12 and 82 of E2 are located in domain A
away from the CHK-265 footprint, suggesting that these muta-
tions do not directly influence the capacity of CHK-265 to recog-
nize the virion. Our data support amodel proposed by Porta et al.
in which pathogenic CHIKV strains possessing the highly
conserved E2 glycine 82 retain domain B flexibility despite
bound antibody, thus permitting viral fusion and entry (Porta
et al., 2015). In contrast, an arginine at E2 residue 82, located
within the core of the E2/E1 trimeric spike, introduces repulsive
forces that alter the spatial conformation of E2 domain B (Fig-
ure S2). This structural perturbation may allow antibodies to
lock domain B into a rigid conformation that impedes exposure
of the E1 fusion loop and entry of the virus into cells. As the E2
domain B appears to be a dominant immune target in
humans and mice (Weger-Lucarelli et al., 2015), the near
uniform conservation of E2 glycine 82 in pathogenic strains
suggests a general mechanism by which CHIKV evades neutral-
izing antibody responses. Based on our findings, we conclude
that this immune evasionmechanism contributes to the develop-
ment of viral persistence. In addition, these findings will enhance
the selection of virus strains used for vaccine development and1336 Cell Reports 16, 1326–1338, August 2, 2016the evaluation of vaccine-induced protective humoral immune
responses.
EXPERIMENTAL PROCEDURES
Viruses
Plasmids encoding infectious cDNA clones of CHIKV strains
SL15649, AF15561, and 181/25 have been previously described (Ashbrook
et al., 2014; Morrison et al., 2011). Virus stocks were prepared from
cDNA clones (Morrison et al., 2011). Viral titers were determined by plaque
assays using BHK-21 and Vero cells as previously described (Hawman
et al., 2013).
Mouse Experiments
Animal experiments were performed with the approval of the Institutional
Animal Care and Use Committee at the University School of Medicine (assur-
ance number: A3269-01). WT, Rag1/, and mMT C57BL/6J mice were ob-
tained from the Jackson Laboratory. Tg(IghelMD4)4Ccg/J (MD4tr) C57BL/6J
mice, which encode a B cell receptor specific for hen egg lysozyme, were
provided by John C. Cambier (University of Colorado School of Medicine).
3-to 4-week-old mice were used for all studies. Mice were inoculated in the
left rear footpad. Animal husbandry and experiments were performed in accor-
dance with all University of Colorado School of Medicine Institutional Animal
Care and Use Committee guidelines. All mouse studies were performed in
an animal biosafety level 3 laboratory.
Quantification of Viral RNA
Viral RNA in tissues and cell culture supernatants was quantified by qRT-PCR
as previously described (Hawman et al., 2013).
Enzyme-Linked Immunosorbent Assay
CHIKV-binding antibodies in mouse sera were quantified using a virion-based
ELISA. Concentrated virus was adsorbed to a 96-well Immulon 4HBX plate
(Thermo Scientific). Serial dilutions of serum were added to the plate, and
bound antibody was detected using biotin-conjugated goat anti-mouse IgM
or IgG antibodies (Southern Biotech), followed by streptavidin conjugated to
horseradish peroxidase (Southern Biotech). Binding was detected using
3,30,5,50-tetramethylbenzidine liquid substrate (Sigma). Endpoint titers were
defined as the reciprocal of the last dilution to have an absorbance two times
greater than background. Blank wells receiving no serum or serum from naive
mice were used to quantify background signal.
Plaque and Focus Reduction Neutralization Tests
Neutralizing activity of murine and human serumwas quantified using a plaque
reduction neutralization test (PRNT). Serum was heat inactivated and serially
diluted. Diluted serum sampleswere incubated with 50 PFUs of challenge virus
for at 37C for 1 hr. Following incubation, remaining infectious virus was quan-
tified by a plaque assay using Vero cells. The PRNT50 value was defined as the
reciprocal of the last dilution to exhibit <50% infectivity. MAbs were tested for
the capacity to neutralize CHIKV using a focus reduction neutralization test as
previously described (Pal et al., 2013).
Statistical Analyses
All data were analyzed using GraphPad Prism (v.6) software. Data were
evaluated for significant differences using a two-tailed, an unpaired t test, a
Mann-Whitney test, and a one-way ANOVA, followed by Tukey’s multiple
comparison test, or by a two-way ANOVA, followed by a Bonferroni post-
test analysis. A p value less than 0.05 was considered statistically significant.
All differences not indicated as significant had a p value greater than 0.05.
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